NASDAQ: BCABBioatla Inc Stock
$2.71-0.20 (-6.87%)
Updated May 10, 2024
BCAB Price
$2.71
Fair Value Price
$2.28
Market Cap
$130.34M
52 Week Low
$1.24
52 Week High
$4.07
P/E
-1.05x
P/B
1.84x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$123.46M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.69
Operating Cash Flow
-$104M
Beta
1.83
Next Earnings
Jun 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BCAB Overview
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BCAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCAB ($2.71) is overvalued by 18.77% relative to our estimate of its Fair Value price of $2.28 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BCAB ($2.71) is not significantly undervalued (18.77%) relative to our estimate of its Fair Value price of $2.28 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BCAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCAB due diligence checks available for Premium users.
Be the first to know about important BCAB news, forecast changes, insider trades & much more!
BCAB News
Valuation
BCAB fair value
Fair Value of BCAB stock based on Discounted Cash Flow (DCF)
Price
$2.71
Fair Value
$2.28
Overvalued by
18.77%
BCAB ($2.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCAB ($2.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BCAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.05x
Industry
6.42x
Market
30.02x
BCAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.84x
Industry
5.91x
BCAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BCAB's financial health
Profit margin
Revenue
$0.0
Net Income
-$26.9M
Profit Margin
0%
BCAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$119.7M
Liabilities
$49.0M
Debt to equity
0.69
BCAB's short-term assets ($116.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCAB's short-term assets ($116.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCAB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.9M
Investing
-$8.0k
Financing
$119.0k
BCAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BCAB vs Biotech Stocks
Bioatla Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.